JP6008116B2 - Oral solution - Google Patents
Oral solution Download PDFInfo
- Publication number
- JP6008116B2 JP6008116B2 JP2012270255A JP2012270255A JP6008116B2 JP 6008116 B2 JP6008116 B2 JP 6008116B2 JP 2012270255 A JP2012270255 A JP 2012270255A JP 2012270255 A JP2012270255 A JP 2012270255A JP 6008116 B2 JP6008116 B2 JP 6008116B2
- Authority
- JP
- Japan
- Prior art keywords
- fatty acid
- unpleasant
- acid ester
- vitamin
- flavor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940100688 oral solution Drugs 0.000 title claims description 4
- -1 fatty acid ester Chemical class 0.000 claims description 38
- 239000007788 liquid Substances 0.000 claims description 34
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 29
- 229930195729 fatty acid Natural products 0.000 claims description 29
- 239000000194 fatty acid Substances 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 28
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 26
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 26
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 23
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 22
- 239000000796 flavoring agent Substances 0.000 claims description 22
- 235000019634 flavors Nutrition 0.000 claims description 22
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 21
- 229960002477 riboflavin Drugs 0.000 claims description 21
- 229930003471 Vitamin B2 Natural products 0.000 claims description 20
- 235000019164 vitamin B2 Nutrition 0.000 claims description 20
- 239000011716 vitamin B2 Substances 0.000 claims description 20
- 239000003205 fragrance Substances 0.000 claims description 15
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 13
- 235000010388 propyl gallate Nutrition 0.000 claims description 10
- 239000000473 propyl gallate Substances 0.000 claims description 10
- 229940075579 propyl gallate Drugs 0.000 claims description 10
- 241000207199 Citrus Species 0.000 claims description 9
- 235000020971 citrus fruits Nutrition 0.000 claims description 9
- 229940049964 oleate Drugs 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229920000223 polyglycerol Polymers 0.000 claims description 6
- 230000001629 suppression Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 description 36
- 230000001953 sensory effect Effects 0.000 description 29
- 230000000052 comparative effect Effects 0.000 description 28
- 235000019645 odor Nutrition 0.000 description 21
- 239000000203 mixture Substances 0.000 description 18
- 239000003814 drug Substances 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
- 239000005642 Oleic acid Substances 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 125000001165 hydrophobic group Chemical group 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 229960004488 linolenic acid Drugs 0.000 description 4
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229940049918 linoleate Drugs 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 244000175448 Citrus madurensis Species 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000017317 Fortunella Nutrition 0.000 description 1
- 235000015030 Hedychium spicatum Nutrition 0.000 description 1
- 240000003237 Hedychium spicatum Species 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241000340987 Ptychopetalum olacoides Species 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- GZQCZDHGTYFJIF-LZWOXQAQSA-N [(2r,3s,4s)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] acetate Chemical compound CC(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O GZQCZDHGTYFJIF-LZWOXQAQSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000009538 yokuinin Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
本発明は、医薬品、医薬部外品、保健機能食品および食品の分野に利用しうる、不飽和脂肪酸を含有するポリグリセリン脂肪酸エステルとビタミンB2を配合した内服液剤に関する。 The present invention relates to an internal liquid preparation containing an unsaturated fatty acid-containing polyglycerin fatty acid ester and vitamin B2, which can be used in the fields of pharmaceuticals, quasi drugs, health functional foods and foods.
ポリグリセリン脂肪酸エステルは、脂溶性の成分を飲料等に溶解させる際に広く用いられるもので、医薬品だけでなく食品の分野でも使用が認められている汎用性の高い界面活性剤である。 Polyglycerin fatty acid esters are widely used when dissolving fat-soluble ingredients in beverages and the like, and are highly versatile surfactants that are recognized not only for pharmaceuticals but also for foods.
ビタミンB2は様々な薬効が知られており、医薬品、医薬部外品、食品などに広く配合されている。目的に応じて脂溶性の有効成分と同時に配合されている。 Vitamin B2 is known to have various medicinal effects and is widely incorporated in pharmaceuticals, quasi drugs, foods and the like. Depending on the purpose, it is blended with fat-soluble active ingredients.
内服液剤にポリグリセリン脂肪酸エステルを用いる場合には、疎水基である脂肪酸の種類や親水基であるポリグリセリンの重合度等の違いにより親水性などの物性が異なる為、溶解させたい脂溶性成分の物性などに合わせて、特定のポリグリセリン脂肪酸エステルを選択して用いるのが一般的である。 When using polyglycerin fatty acid ester as an internal solution, the physical properties such as hydrophilicity differ depending on the type of fatty acid that is a hydrophobic group and the degree of polymerization of polyglycerin that is a hydrophilic group. In general, a specific polyglycerin fatty acid ester is selected and used in accordance with physical properties.
本発明者らは、疎水基が不飽和脂肪酸であるポリグリセリン脂肪酸エステルを用いた場合、疎水基が飽和脂肪酸であるポリグリセリン脂肪酸エステルを用いた場合よりも、浮遊物の発生が抑制され、製剤の長期保存性が優れることがわかった。そこで、疎水基が不飽和脂肪酸であるポリグリセリン脂肪酸エステルを用いて内服液剤を調製したところ、ポリグリセリン脂肪酸エステルの疎水基が不飽和脂肪酸である場合、独特の臭気および呈味を発し、風味の点で課題があることを見出した。さらに、その内服液剤にビタミンB2を同時に配合した場合には、不快味や不快臭の増加が著しいことを発見した。 When the polyglycerin fatty acid ester whose hydrophobic group is an unsaturated fatty acid is used, the present inventors have suppressed the occurrence of suspended matters compared to the case where a polyglycerin fatty acid ester whose hydrophobic group is a saturated fatty acid is used. It was found that the long-term storage stability was excellent. Therefore, when an internal solution was prepared using a polyglycerin fatty acid ester whose hydrophobic group is an unsaturated fatty acid, when the hydrophobic group of the polyglycerin fatty acid ester is an unsaturated fatty acid, it gives off a unique odor and taste, I found that there was a problem in terms of points. Furthermore, when vitamin B2 was mix | blended simultaneously with the internal use liquid agent, it discovered that the increase in an unpleasant taste and an unpleasant odor was remarkable.
これまでに、不飽和脂肪酸を含有した油脂から生じる不快な風味を、没食子酸等を用いて抑制する方法が開示されている。(特許文献1参照)しかしながら、ビタミンB2と不飽和脂肪酸を含有するポリグリセリン脂肪酸エステルを液剤中に同時に配合した場合に、風味にどのような影響を及ぼすのかは知られていない。 Until now, the method of suppressing the unpleasant flavor which arises from the fats and oils containing an unsaturated fatty acid using a gallic acid etc. is disclosed. However, it is not known how the flavor is affected when polyglycerin fatty acid ester containing vitamin B2 and unsaturated fatty acid is blended simultaneously in the liquid preparation.
本発明は、不飽和脂肪酸を含有するポリグリセリン脂肪酸エステルとビタミンB2を同時に配合した内服液剤において生じる、不快風味を抑制することを課題とする。 This invention makes it a subject to suppress the unpleasant flavor which arises in the internal use liquid agent which mix | blended polyglyceryl fatty acid ester and vitamin B2 containing an unsaturated fatty acid simultaneously.
本発明者らは、上記課題を解決すべく鋭意検討を重ねた結果、不飽和脂肪酸を含有するポリグリセリン脂肪酸エステルとビタミンB2を同時に配合した内服液剤に、没食子酸プロピルを配合したこと、また、没食子酸プロピルとシトラス系香料を配合したことにより、経時的に発生する不快味と不快臭が抑制し不快風味が抑制されることを見出し、本発明を完成するに至った。 As a result of intensive studies to solve the above-mentioned problems, the present inventors have formulated propyl gallate in an oral solution containing polyglycerin fatty acid ester containing unsaturated fatty acid and vitamin B2 at the same time, By blending propyl gallate and a citrus fragrance, it was found that the unpleasant taste and unpleasant odor that occur over time are suppressed, and the unpleasant flavor is suppressed, and the present invention has been completed.
即ち本発明は、
(1)不飽和脂肪酸を含有するポリグリセリン脂肪酸エステル、ビタミンB2、及び没食子酸プロピルを配合したことを特徴とする内服液剤、
(2)不飽和脂肪酸を含有するポリグリセリン脂肪酸エステルがポリグリセリンオレイン酸エステルである(1)に記載の内服液剤、
(3)さらにシトラス系香料を配合したことを特徴とする(1)に記載の内服液剤、
(4)没食子酸プロピルを配合したことを特徴とする、ビタミンB2及び不飽和脂肪酸を含有するポリグリセリン脂肪酸エステルを含有する内服液剤の不快風味抑制方法、
(5)さらにシトラス系香料を配合したことを特徴とする、(4)に記載の不快風味抑制方法、
である。
That is, the present invention
(1) An oral liquid preparation comprising a polyglycerin fatty acid ester containing an unsaturated fatty acid, vitamin B2, and propyl gallate,
(2) The internal liquid preparation according to (1), wherein the polyglycerol fatty acid ester containing an unsaturated fatty acid is a polyglycerol oleate ester,
(3) The internal liquid preparation according to (1), further comprising a citrus fragrance,
(4) A method for suppressing an unpleasant flavor of an oral liquid containing a polyglycerin fatty acid ester containing vitamin B2 and an unsaturated fatty acid, characterized by containing propyl gallate
(5) The method for suppressing unpleasant flavor according to (4), further comprising a citrus flavor.
It is.
本発明により、不飽和脂肪酸を含有するポリグリセリン脂肪酸エステルと、ビタミンB2を同時に配合する内服液剤において、経時的に生じる不快味と不快臭を抑制し、不快風味を抑制することができた。 According to the present invention, it was possible to suppress the unpleasant taste and unpleasant odor that occurred over time in the internal liquid preparation containing polyglycerin fatty acid ester containing an unsaturated fatty acid and vitamin B2 at the same time, and to suppress the unpleasant flavor.
本発明における不飽和脂肪酸を含有するポリグリセリン脂肪酸エステルとは、4〜20個のグリセリンが重合したポリグリセリンと炭素数8〜20個で、炭素-炭素間の二重結合を1つ乃至3つもつ脂肪酸を縮合したエステルである。具体的には、ポリグリセリンオレイン酸エステル、ポリグリセリンリノール酸エステル、ポリグリセリンリノレン酸エステルなどが挙げられる。ポリグリセリンオレイン酸エステルとしては、例えばドデカグリセリンオレイン酸エステル、デカグリセリンオレイン酸エステル、ヘキサグリセリンオレイン酸エステルなどが挙げられ、ポリグリセリンリノール酸エステルとしては、ドデカグリセリンリノール酸エステル、デカグリセリンリノール酸エステル、ヘキサグリセリンモノリノール酸エステルなどが挙げられ、ポリグリセリンリノレン酸エステルとしては、例えばドデカグリセリンリノレン酸エステル、デカグリセリンリノレン酸エステル、ヘキサグリセリンモノリノレン酸エステルなどが挙げられる。この中でも特にポリグリセリンオレイン酸エステルが好ましい。 The polyglycerol fatty acid ester containing an unsaturated fatty acid in the present invention is a polyglycerol obtained by polymerizing 4 to 20 glycerol and 8 to 20 carbon atoms, and one to three carbon-carbon double bonds. This ester is a condensed fatty acid. Specific examples include polyglycerin oleate, polyglycerin linoleic acid ester, polyglycerin linolenic acid ester, and the like. Examples of polyglycerin oleate include dodecaglycerin oleate, decaglycerin oleate, hexaglycerin oleate, etc., and polyglycerin linoleate as dodecaglycerin linoleate, decaglycerin linoleate. And hexaglycerin monolinoleic acid ester. Examples of the polyglycerin linolenic acid ester include dodecaglycerin linolenic acid ester, decaglycerin linolenic acid ester, and hexaglycerin monolinolenic acid ester. Among these, polyglycerin oleate is particularly preferable.
本発明の内服液剤において、不飽和脂肪酸を含有するポリグリセリン脂肪酸エステルの配合量は、内服液剤全体に対して0.0001質量%〜10質量%が好ましく、さらに好ましくは0.001質量%〜1質量%である。 In the internal use liquid preparation of the present invention, the blending amount of the polyglycerin fatty acid ester containing an unsaturated fatty acid is preferably 0.0001% by mass to 10% by mass, more preferably 0.001% by mass to 1% with respect to the total internal use liquid preparation. % By mass.
本発明に使用するビタミンB2とは、通常可食性のものをいう。具体的にはリボフラビン、リン酸リボフラビン、酪酸リボフラビン、及びそれらの塩等が挙げられる。本内服液剤中におけるビタミンB2の配合量は、内服液剤全体の0.00005質量%(W/V%)〜5質量%(W/V%)であり、0.0001質量%〜1質量%であることがより好ましく、0.0005質量% 〜0.5質量%が最も好ましい。 Vitamin B2 used in the present invention is usually edible. Specific examples include riboflavin, riboflavin phosphate, riboflavin butyrate, and salts thereof. The compounding quantity of vitamin B2 in this internal use liquid preparation is 0.00005 mass% (W / V%)-5 mass% (W / V%) of the whole internal use liquid preparation, 0.0001 mass%-1 mass%. More preferably, 0.0005% by mass to 0.5% by mass is most preferable.
本発明に係る内服液剤において、没食子酸プロピルの配合量はビタミンB2 1質量部に対して通常0.0001質量部〜10000質量部であり、好ましくは0.001質量部〜5000質量部であり、より好ましくは0.01質量部〜1000質量部である。 In the internal use liquid preparation according to the present invention, the amount of propyl gallate is usually 0.0001 parts by mass to 10,000 parts by mass, preferably 0.001 parts by mass to 5000 parts by mass with respect to 1 part by mass of vitamin B2. More preferably, it is 0.01 mass part-1000 mass parts.
本発明に使用するシトラス系香料とは、ミカン科のミカン属・キンカン属・カラタチ属の植物の加工物と同等の香気を有するものであれば特に制限されない。具体的には、オレンジフレーバー、ライムフレーバー、グレープフルーツフレーバー、マンダリンフレーバーなどが挙げられる。これら香料は、天然香料、合成香料、調合香料の何れも用いることができ、産業上入手することも可能である。本発明の飲料におけるこれら香料の配合量は内服液剤全体に対して0.001〜1質量%、好ましくは0.01〜0.5質量%である。 The citrus fragrance used in the present invention is not particularly limited as long as it has a fragrance equivalent to a processed product of the citrus genus, kumquat genus, and karatachi genus of the citrus family. Specific examples include orange flavor, lime flavor, grapefruit flavor, and mandarin flavor. As these fragrances, any of natural fragrances, synthetic fragrances, and blended fragrances can be used, and they can be obtained industrially. The compounding quantity of these fragrance | flavors in the drink of this invention is 0.001-1 mass% with respect to the whole internal use liquid agent, Preferably it is 0.01-0.5 mass%.
本発明の内服液剤の好ましいpHは2.5〜7.0である。pHが2.5未満であると商品性上好ましくないためである。pHの調整には、例えば、クエン酸、リンゴ酸、フマル酸、酒石酸、乳酸、コハク酸などの有機酸又は有機酸の塩、リン酸、塩酸などの無機酸、水酸化ナトリウム、水酸化カリウムなどの無機塩基を用いることができる。 The preferred pH of the internal solution of the present invention is 2.5 to 7.0. This is because a pH of less than 2.5 is not preferable in terms of commercial properties. For adjusting the pH, for example, citric acid, malic acid, fumaric acid, tartaric acid, lactic acid, salts of organic acids such as succinic acid, inorganic acids such as phosphoric acid, hydrochloric acid, sodium hydroxide, potassium hydroxide, etc. Inorganic bases can be used.
また、本発明の内服液剤には、脂溶性成分を配合してもよい。脂溶性成分としては、ビタミンA、ビタミンD、ビタミンE、ビタミンK、酢酸リボフラビン、γ−オリザノール等のビタミン類及びその誘導体、カプリル酸トリグリセライド、トリ(カプリル/カプリン酸)グリセリル等の中鎖脂肪酸トリグリセライド、γ−リノレン酸等のトリグリセリン脂肪酸エステル、生薬乾燥粉末、抽出エキス、流エキス等の生薬抽出物等が挙げられる。
尚、生薬としてはイカリソウ、オウギ、オウセイ、オンジ、カイクジン、カイバ、カシュウ、カンゾウ、クコシ、ケイヒ、ゴオウ、ゴミシ、サイコ、サンヤク、サンシュユ、ジオウ、シャクヤク、ジャショウシ、シュクシャ、ショウキョウ、ジョテイシ、センキュウ、タイソウ、チンピ、トウキ、トウチュウカソウ、トシシ、トチュウ、トチュウヨウ、ニクジュヨウ、ニンジン、バクモンドウ、ハゲキテン、ハンピ、ビャクジュツ、ブクリョウ、ムイラプアマ、ヨクイニン、リュウガンニク、ロクジョウ等が挙げられる。
Moreover, you may mix | blend a fat-soluble component with the internal use liquid agent of this invention. As fat-soluble components, vitamins such as vitamin A, vitamin D, vitamin E, vitamin K, riboflavin acetate and γ-oryzanol and their derivatives, medium chain fatty acid triglycerides such as caprylic acid triglyceride and tri (caprylic / capric acid) glyceryl And herbal medicine extracts such as triglycerin fatty acid esters such as γ-linolenic acid, herbal medicine dry powder, extract extract, flow extract, and the like.
Herbal medicines include Ikarisou, Ogi, Ousei, Onji, Kaikujin, Kaiba, Kashiwa, Kanzo, Kukoshi, Keihi, Gooh, Garbage, Psycho, Sanyaku, Sanshuyu, Giou, Peonies, Jashoushi, Shukusha, Shokyo, Jyoshi, Senkyu, Examples include Taisou, Chinpi, Toki, Tochukaso, Toshishi, Tochu, Tochu, Nikujuyo, Carrot, Bakumondo, Vulture, Hampi, Byakutsu, Bukkyou, Muirapuama, Yokuinin, Ryuganiku, Rokujo and the like.
本発明の内服液剤には、ビタミン類、ミネラル類、生薬、生薬抽出物などを本発明の効果を損なわない範囲で適宜に配合できる。また、必要に応じて甘味剤、着色剤、香料、界面活性剤、溶解補助剤、保存剤などの添加物を本発明の効果を損なわない範囲で適宜に配合できる。これらの添加物等は、1種で単独に配合しても、2種以上を適宜組み合わせて配合してもよい。 Vitamins, minerals, herbal medicines, herbal extracts and the like can be appropriately added to the internal liquid preparation of the present invention as long as the effects of the present invention are not impaired. In addition, additives such as sweeteners, colorants, fragrances, surfactants, solubilizing agents, preservatives and the like can be appropriately blended as necessary so long as the effects of the present invention are not impaired. These additives and the like may be blended singly or in combination of two or more.
本発明の内服液剤を調製する方法は、本発明の効果を奏する限り、特に限定されるものではなく、通常、各成分を適量の精製水で溶解した後、pH及び容量を、残りの精製水を加えて調整し、必要に応じてろ過、殺菌処理する方法である。ビタミンB2および没食子酸プロピルを配合する方法は特に限定されず、他の成分と同様である。 The method for preparing the internal liquid preparation of the present invention is not particularly limited as long as the effects of the present invention are exhibited. Usually, after dissolving each component with an appropriate amount of purified water, the pH and volume are adjusted to the remaining purified water. It is the method of adding and adjusting, and filtering and sterilizing as needed. The method of blending vitamin B2 and propyl gallate is not particularly limited and is the same as other components.
また、本発明の内服液剤に脂溶性成分を配合する場合は、例えば次のように製造される。脂溶性成分、不飽和脂肪酸を含有するポリグリセリン脂肪酸エステルに対して水を混合し、攪拌槽全体が均一になるまで加熱攪拌する。加熱温度については、攪拌槽全体が均一になればよいが、不飽和脂肪酸を含有するポリグリセリン脂肪酸エステルの種類によっては常温で固形及び半固形状態のものもあり、攪拌混合時の流動性を上げるためなるべく70℃以上が好ましい。 Moreover, when mix | blending a fat-soluble component with the internal use liquid agent of this invention, it manufactures as follows, for example. Water is mixed with the polyglycerin fatty acid ester containing the fat-soluble component and the unsaturated fatty acid, and the mixture is heated and stirred until the entire stirring tank becomes uniform. Regarding the heating temperature, it is sufficient that the entire stirring tank is uniform, but depending on the type of polyglycerin fatty acid ester containing unsaturated fatty acid, there are solid and semi-solid states at room temperature, which increases fluidity during stirring and mixing. Therefore, 70 degreeC or more is preferable if possible.
本発明の内服液剤は、例えばシロップ剤、ドリンク剤などの医薬品や指定医薬部外品、保健機能食品および食品などとして提供することができる。 The internal liquid preparation of the present invention can be provided as, for example, pharmaceutical products such as syrups and drinks, designated quasi-drugs, health functional foods and foods.
以下に、実施例、比較例及び試験例等を挙げ、本発明をさらに詳細に説明するが、本発明はこれらの実施例等に何ら限定されるものではない。
下表1〜表2に、実施例1〜9と比較例1〜9処方を示した。表1〜表2に記載の処方の各成分を秤量して、精製水に溶解させ、pHを3.0になるよう、かつ、内服液剤の全量が100mLとなるよう調整した。その後にガラス瓶に充填し、キャップを施して実施例1〜9並びに比較例1〜9の内服液剤を得た。
Hereinafter, the present invention will be described in more detail with reference to Examples, Comparative Examples, and Test Examples, but the present invention is not limited to these Examples.
In Tables 1 and 2 below, Examples 1 to 9 and Comparative Examples 1 to 9 are shown. Each component of the formulation described in Tables 1 and 2 was weighed and dissolved in purified water, and the pH was adjusted to 3.0, and the total amount of internal solution was adjusted to 100 mL. After that, it filled into the glass bottle, the cap was given, and the internal use liquid agent of Examples 1-9 and Comparative Examples 1-9 was obtained.
試験例1
表2に記載の比較例1〜4で示した組成の内服液剤の調製直後の不快臭及び不快味の強度の評価を6名の専門パネルにより行った。表3の基準で官能評価を行い、その平均値を求めた。その結果を図1及び図2に示す。
Test example 1
Evaluation of the intensity of unpleasant odor and unpleasant taste immediately after the preparation of the internal liquid preparations having the compositions shown in Comparative Examples 1 to 4 shown in Table 2 was performed by 6 specialist panels. Sensory evaluation was performed according to the criteria in Table 3, and the average value was obtained. The results are shown in FIGS.
図1及び図2に示した実験結果から明らかなように、不飽和脂肪酸であるオレイン酸を含有する界面活性剤を配合した比較例2は、界面活性剤を配合しない比較例1や、不飽和脂肪酸を含有しないポリグリセリン脂肪酸エステルを配合した比較例3及び4と比較し、不快な風味と不快臭が特異的に強い事がわかった。 As is apparent from the experimental results shown in FIG. 1 and FIG. 2, Comparative Example 2 in which a surfactant containing oleic acid, which is an unsaturated fatty acid, was blended, Comparative Example 1 in which no surfactant was blended, and unsaturated It was found that the unpleasant flavor and unpleasant odor were specifically strong as compared with Comparative Examples 3 and 4 containing a polyglycerin fatty acid ester not containing a fatty acid.
試験例2
表2に記載の比較例2で示す組成の内服液剤の調製後65℃で3日間加温したものと加温せずに調整後5℃で保管したものの不快臭及び不快味の強度の評価を6名の専門パネルにより行った。表3の基準で官能評価を行い、その平均値を求めた。その結果を図3及び図4に示す。
図3及び図4に示した実験結果から明らかなように、不飽和脂肪酸であるオレイン酸を含有する界面活性剤を配合した比較例2は、熱により不快臭が継時的に増加することが分かった。
Test example 2
Evaluation of strength of unpleasant odor and unpleasant taste of preparations for internal liquids having the composition shown in Comparative Example 2 shown in Table 2 after heating at 65 ° C. for 3 days and storage without adjustment at 5 ° C. It was conducted by 6 specialist panels. Sensory evaluation was performed according to the criteria in Table 3, and the average value was obtained. The results are shown in FIGS.
As is apparent from the experimental results shown in FIGS. 3 and 4, in Comparative Example 2 in which a surfactant containing oleic acid, which is an unsaturated fatty acid, was blended, the unpleasant odor may increase over time due to heat. I understood.
試験例3
表2に記載の比較例5で示す組成の内服液剤の調製後光の照射を行わずに5℃で保管したもの及び調製後白色蛍光灯により60万lx・hrの光を照射したものの不快臭及び不快味の強度の評価を6名の専門パネルにより行った。表3の基準で官能評価を行い、その平均値を求めた。その結果を図5及び図6に示す。
図5及び図6に示した実験結果から明らかなように、不飽和脂肪酸であるオレイン酸を含有する界面活性剤を配合した比較例5は、光照射により、不快臭や不快味が継時的に増加することが分かった。
Test example 3
Unpleasant odors of preparations of internal liquids having the composition shown in Comparative Example 5 shown in Table 2 that were stored at 5 ° C. without being irradiated with light and those that were irradiated with 600,000 lx · hr of light after preparation with a white fluorescent lamp And the evaluation of the intensity of unpleasant taste was performed by 6 specialist panels. Sensory evaluation was performed according to the criteria in Table 3, and the average value was obtained. The results are shown in FIGS.
As is apparent from the experimental results shown in FIGS. 5 and 6, Comparative Example 5 containing a surfactant containing oleic acid, which is an unsaturated fatty acid, has an unpleasant odor and unpleasant taste due to light irradiation over time. It turned out to increase.
試験例4
表2に記載の比較例6〜7で示す組成の内服液剤を調製後65℃で1日間保存したものの不快臭及び不快味を比較例5で示す組成の内服液剤を調製後65℃で1日間保存したものと相対的に評価した結果と、比較例6〜8で示す組成の内服液剤を調製後白色蛍光灯により60万lx・hrの光を照射したものの不快臭及び不快味を比較例5で示す組成の内服液剤を白色蛍光灯により60万lx・hrの光を照射したものと相対的に評価した結果を図7及び図8に示す。なお、評価は、6名の専門パネルにより表4の基準で行い、その平均値を求めた。
Test example 4
After preparing the oral solution of the composition shown in Table 2 in Comparative Examples 6 to 7 and stored at 65 ° C. for 1 day, the unpleasant odor and unpleasant taste of the composition shown in Comparative Example 5 after preparation of the internal solution of 65 ° C. for 1 day Comparative Example 5 shows the unpleasant odor and unpleasant taste of the results of relative evaluation with the stored ones and those irradiated with 600,000 lx · hr of light with a white fluorescent lamp after preparing the internal liquid preparations of the compositions shown in Comparative Examples 6-8. 7 and FIG. 8 show the results of a relative evaluation of the internal liquid preparation having the composition shown in FIG. 7 that was irradiated with 600,000 lx · hr of light with a white fluorescent lamp. The evaluation was performed according to the criteria shown in Table 4 by 6 expert panels, and the average value was obtained.
図7及び図8に示した実験結果から明らかなように、不飽和脂肪酸であるオレイン酸を含有する界面活性剤に加え、ビタミンB2を配合した比較例6〜8は、ビタミンB2を配合しない比較例5よりも、不快臭や不快味が強くなることが分かった。 As is apparent from the experimental results shown in FIGS. 7 and 8, Comparative Examples 6 to 8 in which vitamin B2 was added in addition to the surfactant containing oleic acid, which is an unsaturated fatty acid, were not compared with vitamin B2. It was found that the unpleasant odor and unpleasant taste were stronger than Example 5.
試験例5
表1に記載の実施例1〜3並びに表2に記載の比較例6、9で示す組成の内服液剤を調製後65℃で1日間保存したものの不快臭及び不快味の強度の評価結果を6名の専門パネルにより行った。表3の基準で官能評価を行い、その平均値を求めた。その結果を図9及び図10に示す。
図9及び図10に示した実験結果から明らかなように、不飽和脂肪酸であるオレイン酸を含有する界面活性剤に加え、ビタミンB2を配合した際に生じる不快な風味は、没食子酸プロピルを添加することにより抑制でき(実施例1〜3)、その効果は一般に不快な風味のマスキングで用いられるシクロデキストリン(比較例9)と比較して顕著であることが分かった。
Test Example 5
The evaluation results of the intensity of unpleasant odor and unpleasant taste of preparations of internal liquid preparations of the compositions shown in Examples 1 to 3 shown in Table 1 and Comparative Examples 6 and 9 shown in Table 2 were stored at 65 ° C. for 1 day. It was done by a specialized panel of names. Sensory evaluation was performed according to the criteria in Table 3, and the average value was obtained. The results are shown in FIGS.
As apparent from the experimental results shown in FIGS. 9 and 10, in addition to the surfactant containing oleic acid, which is an unsaturated fatty acid, propyl gallate is added as an unpleasant flavor that occurs when vitamin B2 is added. (Examples 1 to 3), and the effect was found to be remarkable compared with cyclodextrin (Comparative Example 9) generally used for masking of unpleasant flavors.
試験例6
表1に記載の実施例1、4〜9で示す組成の内服液剤を調製後、白色蛍光灯により60万lx・hrの光を照射した。実施例1に対して、実施例4〜9を相対的に評価した結果と不快臭及び不快味の強度の評価を6名の専門パネルにより行った。表4の基準で官能評価を行い、その平均値を求めた。その結果を図11及び図12に示す。
図11及び図12に示した実験結果から明らかなように、没食子酸プロピルに加え、香料を添加した実施例4〜9は、添加していない実施例1と比較してさらに不快な風味を抑制できたが、特にシトラス系香料(実施例7〜9)を添加すると不快な風味の抑制効果が顕著であることがわかった。
Test Example 6
After preparing the internal liquid preparations having the compositions shown in Examples 1 and 4 to 9 shown in Table 1, 600,000 lx · hr of light was irradiated with a white fluorescent lamp. The result of relatively evaluating Examples 4 to 9 and the intensity of unpleasant odor and unpleasant taste were evaluated by Example 6 with respect to Example 1. Sensory evaluation was performed based on the criteria in Table 4, and the average value was obtained. The results are shown in FIGS.
As is apparent from the experimental results shown in FIGS. 11 and 12, Examples 4 to 9 to which fragrance was added in addition to propyl gallate further suppressed unpleasant flavor as compared to Example 1 to which fragrance was not added. Although it was able to be done, it turned out that especially when a citrus fragrance | flavor (Examples 7-9) is added, the inhibitory effect of an unpleasant flavor is remarkable.
実施例10、11
下記表5に実施例10、11の処方を示した。表5に記載の各成分を秤量し、脂溶性成分であるビタミンEとニンジンエキスはポリグリセリンオレイン酸エステルと混合し、攪拌槽全体が均一になるまで加熱攪拌した。その後、他の成分と共に精製水に溶解させ、pHを3.0になるよう、かつ、内服液剤の全量が100mLとなるよう調整した。その後にガラス瓶に充填し、キャップを施して内服液剤を得た。
Examples 10 and 11
Table 5 below shows the formulations of Examples 10 and 11. Each component described in Table 5 was weighed, and vitamin E and carrot extract, which are fat-soluble components, were mixed with polyglycerin oleate and heated and stirred until the entire stirring tank was uniform. Then, it was made to melt | dissolve in purified water with other components, and it adjusted so that pH might be set to 3.0 and the total amount of internal use liquid agent might be 100 mL. Thereafter, it was filled into a glass bottle and a cap was applied to obtain an internal solution.
本発明により、不飽和脂肪酸を含有するポリグリセリン脂肪酸エステルとビタミンB2を同時に配合する内服液剤を製造することが可能となったので、医薬品、指定医薬部外品、食品などの分野において、商品性の高い、不飽和脂肪酸を含有するポリグリセリン脂肪酸エステル及びビタミンB2配合内服液剤を提供することが期待される。 According to the present invention, it is possible to produce an internal liquid preparation containing an unsaturated fatty acid-containing polyglycerin fatty acid ester and vitamin B2 at the same time. Therefore, in the fields of pharmaceuticals, designated quasi drugs, foods, etc. It is expected to provide a liquid composition containing a polyglycerin fatty acid ester and a vitamin B2 containing an unsaturated fatty acid.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012270255A JP6008116B2 (en) | 2011-12-14 | 2012-12-11 | Oral solution |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011273002 | 2011-12-14 | ||
JP2011273002 | 2011-12-14 | ||
JP2012270255A JP6008116B2 (en) | 2011-12-14 | 2012-12-11 | Oral solution |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013144674A JP2013144674A (en) | 2013-07-25 |
JP6008116B2 true JP6008116B2 (en) | 2016-10-19 |
Family
ID=49040699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012270255A Active JP6008116B2 (en) | 2011-12-14 | 2012-12-11 | Oral solution |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6008116B2 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0768126B2 (en) * | 1990-09-04 | 1995-07-26 | 太陽化学株式会社 | Carcinogenic promotion inhibitor |
JP3460089B2 (en) * | 1991-12-10 | 2003-10-27 | 第一薬品工業株式会社 | Internal liquids that prevent off-flavor generation |
CN1794922A (en) * | 2003-06-26 | 2006-06-28 | 三菱化学株式会社 | Polyglycerin fatty acid esters and emulsified or solubilized compositions comprising them |
JP5040060B2 (en) * | 2004-10-14 | 2012-10-03 | 大正製薬株式会社 | Methionine combination oral solution |
US8173876B2 (en) * | 2010-03-05 | 2012-05-08 | Harris Moran Seed Company | Garden bean cultivar H37118 |
-
2012
- 2012-12-11 JP JP2012270255A patent/JP6008116B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2013144674A (en) | 2013-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6134049B2 (en) | Product of water-soluble derivative of vitamin E and composition containing the same | |
US10874122B2 (en) | Beverage compositions containing non-polar compounds | |
JP5150490B2 (en) | Squalene-containing oily composition and squalene-containing oil-in-water emulsion | |
WO2010074163A1 (en) | Complex and manufacturing method therefor | |
JP2007289124A (en) | Emulsified composition | |
CA2840891A1 (en) | Stable fatty acid-containing formulations | |
JP2012012308A (en) | Complex and method for producing the same | |
JP2007209251A (en) | Coenzyme q10-containing composition | |
JP6047404B2 (en) | Physiologically active substance-containing water-soluble preparation and method for producing the same | |
JP6008116B2 (en) | Oral solution | |
JP2005343799A (en) | Water-dispersible plant sterol preparation and oil and fat-containing water-dispersible plant sterol preparation | |
JPH06169735A (en) | Nutritious drink composition | |
JP2015192661A (en) | herbal extract-containing beverage | |
JP6639892B2 (en) | Gamma-oryzanol solubilized liquid composition | |
JP2010150163A (en) | Compound material and method for producing the same | |
WO2007046333A1 (en) | Emulsifying agent and emulsion composition prepared with the same | |
JP2007016000A (en) | Thioctic acid-containing composition | |
JP6260538B2 (en) | Oral liquid composition | |
JP2007063204A (en) | Saw palmetto extract-containing aqueous composition | |
JP2000139345A (en) | Glycolipid-containing emulsified composition and its production | |
KR101142419B1 (en) | Composition for absorption force of ginsenoside compound k | |
JP2014193132A (en) | Pentacyclic triterpene acid-containing composition, and method for manufacturing the same | |
JP6024371B2 (en) | Herbal extract-containing liquid composition | |
KR20230093173A (en) | Emulsions for enhancing stability of unsaturated fatty acid using cellulose and antioxidants and preparation method thereof | |
JP2018201344A (en) | Water-soluble powder containing plant extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151126 |
|
TRDD | Decision of grant or rejection written | ||
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160812 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160817 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160830 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6008116 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |